PMC:7242013 / 14791-15310
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 435 | 111-121 | Species | denotes | SARS‐CoV‐2 | Tax:2697049 |
| 436 | 301-312 | Species | denotes | participant | Tax:9606 |
| 437 | 266-274 | Disease | denotes | COVID‐19 | MESH:C000657245 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T179 | 111-115 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T180 | 266-274 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T157 | 0-131 | Sentence | denotes | Both APASL and AASLD recommend using alternative physical distancing processes for study assessments to reduce SARS‐CoV‐2 exposure. |
| T158 | 132-390 | Sentence | denotes | APASL specifically recommends seeking local regulators and institutional review board approval of the contingency measures during the COVID‐19 pandemic, obtaining trial participant’s consent, and documentation of all deviations from the contingency measures. |
| T159 | 391-516 | Sentence | denotes | These recommendations align with US National Institutes of Health (NIH) revised guidance for NIH‐supported clinical research. |
| T160 | 517-519 | Sentence | denotes | 10 |